Cargando…

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics

INTRODUCTION: In the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed the rate of decline in forced vital capacity (FVC; mL/year) over 52 weeks compared with placebo. We assessed the efficacy of nintedanib across subgroup...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolb, Martin, Flaherty, Kevin R., Silva, Rafael S., Prasse, Antje, Vancheri, Carlo, Mueller, Heiko, Sroka-Saidi, Kamila, Wells, Athol U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611817/ https://www.ncbi.nlm.nih.gov/pubmed/37751022 http://dx.doi.org/10.1007/s12325-023-02668-x

Ejemplares similares

Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
por: Noth, Imre, et al.
Publicado: (2019)

Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial
por: Matteson, Eric L., et al.
Publicado: (2023)

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
por: Fletcher, Sophie V., et al.
Publicado: (2018)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?
por: Cottin, Vincent, et al.
Publicado: (2022)

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
por: Behr, Jürgen, et al.
Publicado: (2019)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
por: Guenther, Andreas, et al.
Publicado: (2018)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Nintedanib Treatment for Idiopathic Pulmonary Fibrosis Patients Who Have Been Switched from Pirfenidone Therapy: A Retrospective Case Series Study
por: Vianello, Andrea, et al.
Publicado: (2020)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications
por: Wells, Athol U
Publicado: (2013)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Effects of Nintedanib in an Animal Model of Liver Fibrosis
por: Wollin, Lutz, et al.
Publicado: (2020)

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
por: Matteson, Eric L., et al.
Publicado: (2022)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
por: Ogata, Hiroaki, et al.
Publicado: (2021)

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
por: Kato, Kosuke, et al.
Publicado: (2021)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
por: Raman, Lavanya, et al.
Publicado: (2023)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience
por: Mullerpattan, Jai B, et al.
Publicado: (2019)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020)

Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis
por: Nemoto, Masahiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6u3snjheitub8gjphen4mugv1e